Cough Augmentation Techniques in the Critically Ill: A Canadian National Survey.

Respir Care

Ottawa Hospital Respiratory Rehabilitation Center, the Ottawa Hospital Sleep Centre, and the University of Ottawa, Ottawa, Ontario, Canada.

Published: October 2016

AI Article Synopsis

  • Critically ill patients on mechanical ventilation struggle with airway clearance, leading to the use of cough augmentation techniques like mechanical insufflation-exsufflation (MI-E), manually assisted cough, and lung volume recruitment to enhance coughing efficiency.
  • A survey of Canadian healthcare units found that 50% utilized cough augmentation, with MI-E being the most common method, primarily indicated for secretion clearance in patients with neuromuscular diseases and spinal cord injuries.
  • Common barriers to using these techniques included a lack of expertise (70%), knowledge (65%), and resources (52%), while complications varied, including pneumothorax for MI-E and chest pain for manually assisted cough.

Article Abstract

Background: Critically ill mechanically ventilated patients experience impaired airway clearance due to ineffective cough and impaired secretion mobilization. Cough augmentation techniques, including mechanical insufflation-exsufflation (MI-E), manually assisted cough, and lung volume recruitment, improve cough efficiency. Our objective was to describe use, indications, contraindications, interfaces, settings, complications, and barriers to use across Canada.

Methods: An e-mail survey was sent to nominated local survey champions in eligible Canadian units (ICUs, weaning centers, and intermediate care units) with 4 telephone/e-mail reminders.

Results: The survey response rate was 157 of 238 (66%); 78 of 157 units (50%) used cough augmentation, with 50 (64%) using MI-E, 53 (68%) using manually assisted cough, and 62 (79%) using lung volume recruitment. Secretion clearance was the most common indication (MI-E, 92%; manually assisted cough, 88%; lung volume recruitment, 76%), although the most common units (44%) used it <50% of the time. Use during weaning from invasive (MI-E, 21%; manually assisted cough, 39%; lung volume recruitment, 3%) and noninvasive ventilation (MI-E, 21%; manually assisted cough, 33%; lung volume recruitment, 21%) was infrequent. The most common diagnoses were neuromuscular disease (97%) and spinal cord injury (83%). Pneumothorax was the most frequently identified absolute contraindication for MI-E (93%) and lung volume recruitment (83%); rib fracture was most frequently identified for manually assisted cough (69%). MI-E mean inspiratory pressure was 31 cm H2O, and expiratory pressure was -32 cm H2O. Mucus plugging requiring tracheostomy inner change was the most frequent complication for MI-E (23%), chest pain for manually assisted cough (36%), and hypotension for lung volume recruitment (17%). The most commonly cited barriers were lack of expertise (70%), knowledge (65%), and resources (52%).

Conclusions: We found moderate adoption of cough augmentation techniques, particularly for secretion management. Lack of expertise and knowledge are potentially modifiable barriers addressed with educational interventions.

Download full-text PDF

Source
http://dx.doi.org/10.4187/respcare.04775DOI Listing

Publication Analysis

Top Keywords

cough augmentation
12
manually assisted
12
assisted cough
12
lung volume
12
volume recruitment
12
cough
8
augmentation techniques
8
critically ill
8
techniques critically
4
ill canadian
4

Similar Publications

Article Synopsis
  • Patients with refractory chronic cough (RCC) are increasingly visiting otolaryngology clinics, requiring better evaluation and management after standard treatments have failed.
  • This review highlights new treatment options for RCC, focusing on disrupting the hypersensitive cough reflex through various methods such as neuromodulators, nerve blockades, and behavioral therapies.
  • Understanding these emerging strategies is essential for improving treatment outcomes as more patients seek specialized care for RCC in otolaryngology.
View Article and Find Full Text PDF

Alpha-1 antitrypsin inhibits pertussis toxin.

J Biol Chem

October 2024

Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, Ulm University Medical Center, Ulm, Germany. Electronic address:

Pertussis (whooping cough) is a vaccine-preventable but re-emerging, highly infectious respiratory disease caused by Bordetella pertussis. There are currently no effective treatments for pertussis, complicating care for nonvaccinated individuals, especially newborns. Disease manifestations are predominantly caused by pertussis toxin (PT), a pivotal virulence factor classified as an ADP-ribosylating AB-type protein toxin.

View Article and Find Full Text PDF

Background: The clinical effectiveness of early therapies for mild-to-moderate COVID-19, comparing antivirals and monoclonal antibodies (mAbs) during the Omicron era, has not been conclusively assessed through a post-approval comparative trial. We present a pooled analysis of two randomized clinical trials conducted during Omicron waves.

Methods: The MANTICO2/MONET trial is a pooled analysis of two multicentric, independent, phase-4, three-arm, superiority, randomized, open-label trials.

View Article and Find Full Text PDF

A Scoping Review of Fall-Risk Screening Tools in the Emergency Department for Future Falls in Older Adults.

Gerontology

December 2024

Australian Centre for Health Services Innovation and Centre for Healthcare Transformation, School of Public Health and Social Work, Faculty of Health, Queensland University of Technology, Kelvin Grove, Queensland, Australia.

Background: Approximately one-third of adults over the age of 65 experience falls annually, with half resulting in injury. Peak bodies have recommended the use of fall-risk screening tools in the emergency department (ED) to identify patients requiring in-depth assessment and potential fall-prevention intervention. This study aimed to examine the scope of published studies on fall-risk screening tools used in the ED and evidence of associations between screening and future falls.

View Article and Find Full Text PDF

Patients with spinal muscular atrophy type 1 (SMA-1) requiring invasive ventilation can be eligible for gene therapy if they tolerate at least 8 h off ventilation per day. We aimed to assess the short-term safety and efficacy of gene therapy (onasemnogene abeparvovec; Zolgensma) on respiratory function in SMA-1 patients ventilated via tracheostomy pre-gene therapy. A prospective cohort study included 22 patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!